LyGenesis CEO Michael Hufford joins Prime Movers Lab Partner Gavin Mathis to discuss Michael's extensive background in drug development and the innovative work being done at LyGenesis in regenerative medicine. The company has found a way to turn lymph nodes into bioreactors to grow functioning ectopic organs, particularly the liver. Michael shares insights into their clinical trials, the economic implications of their therapies, and the broader applications of their technology. He also addresses the regulatory landscape and personal reflections on the challenges and future of regenerative medicine.

Chapters

00:00 Introduction to LightGenesis and Michael Hufford

03:53 Innovative Approaches in Regenerative Medicine

10:00 Clinical Trials and Liver Regeneration

15:11 Economic Impact of Liver Therapy

19:50 Expanding Applications Beyond the Liver

24:52 Regulatory Landscape and Challenges

29:03 Personal Insights and Future Predictions